Fulcrum Therapeutics, Inc.
FULC
$6.67
$0.152.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -- | 8,990.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -- | 8,990.91% |
| Cost of Revenue | -24.76% | -32.21% | -38.35% | -19.73% | -3.29% |
| Gross Profit | -120.70% | 32.21% | 35.39% | 16.25% | 469.73% |
| SG&A Expenses | -33.37% | -30.43% | -21.78% | -15.43% | -0.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.97% | -31.61% | -32.69% | -18.21% | -2.36% |
| Operating Income | -137.75% | 31.61% | 30.59% | 15.95% | 292.33% |
| Income Before Tax | -131.22% | 34.29% | 33.07% | 9.66% | 332.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -131.22% | 34.29% | 33.07% | 9.66% | 332.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -131.22% | 34.29% | 33.07% | 9.66% | 332.98% |
| EBIT | -137.75% | 31.61% | 30.59% | 15.95% | 292.33% |
| EBITDA | -136.83% | 31.70% | 30.65% | 15.66% | 297.82% |
| EPS Basic | -131.04% | 34.81% | 23.24% | 10.53% | 331.41% |
| Normalized Basic EPS | -131.04% | 34.81% | 23.27% | 19.03% | 331.48% |
| EPS Diluted | -132.18% | 34.81% | 22.49% | 10.26% | 326.03% |
| Normalized Diluted EPS | -131.73% | 34.81% | 23.27% | 19.03% | 326.44% |
| Average Basic Shares Outstanding | 0.54% | 0.80% | -12.80% | 0.95% | 0.67% |
| Average Diluted Shares Outstanding | -1.64% | 0.80% | -12.80% | 0.95% | 2.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |